Tepnel Completes Acquisition of Orchid's Diagnostics Unit
Under the terms of the agreement, Tepnel has acquired the product and services business of Orchid Diagnostics unit in the U.S., the U.K. and Belgium, including its LifeMatch(TM) system and consumable product line for HLA testing and its Elucigene(TM) product line for testing of certain genetic diseases, as well as certain liabilities of the diagnostics business.
Tepnel has taken control f the facilities formerly occupied by Orchid's diagnostic unit in Stamford, Connecticut and Brussels, Belgium, and has indicated its intention to retain all of the diagnostics unit's employees.
Other news from the department
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.